Two million prescription for aspirin are handed out in England every month. It’s easy to see why. The drug effectively eases mild aches and pains while also slashing the risk of death from heart ...

ATLANTA, GA (May 20, 2022) – Results from a real-world study investigating safety and effectiveness of clopidogrel versus aspirin monotherapy beyond 12 months after PCI in high-risk patients during ...

A P2Y12 inhibitor, such as clopidogrel or ticagrelor, might be a better choice than aspirin for antiplatelet monotherapy in patients with coronary artery disease, results of a new meta-analysis ...

A new study suggests blood thinner clopidogrel may offer superior protection against heart attacks and strokes compared to aspirin for patients with a specific form of heart disease. Crucially, the ...

Dual antiplatelet treatment has been shown to lower the risk of recurrent stroke as compared with aspirin alone when treatment is initiated early (≤24 hours) after an acute mild stroke. The effect of ...

Groundbreaking research unveiled at the European Society of Cardiology congress in Madrid has suggested aspirin may not be the gold standard for preventing heart attacks in heart patients after all.

More-aggressive antiplatelet therapy with a P2Y12 inhibitor—either clopidogrel or ticagrelor (Brilinta; AstraZeneca)—for secondary prevention is associated with a lower risk of atherothrombotic events ...

A commonly prescribed drug could be more effective than aspirin for long-term heart disease prevention. Analysis of nearly 29,000 patients with coronary artery disease (CAD) suggests the blood thinner ...

Antiplatelet drug therapy has become one of the cornerstones of treatment for patients with cardiovascular disease. Large clinical trials have shown that antiplatelet medications have important ...

Clopidogrel is a generic prescription medication. It is FDA-approved to help prevent cardiovascular events such as heart attack and stroke in certain adults. Specifically, clopidogrel is approved to ...

The effect of single as compared with dual antiplatelet treatment on bleeding and thromboembolic events after transcatheter aortic-valve implantation (TAVI) in patients who do not have an indication ...